Zenas BioPharma, Inc. (NASDAQ:ZBIO - Get Free Report) shares were down 8.8% during mid-day trading on Tuesday . The stock traded as low as $15.32 and last traded at $15.33. Approximately 80,218 shares changed hands during mid-day trading, a decline of 56% from the average daily volume of 183,143 shares. The stock had previously closed at $16.81.
Analyst Upgrades and Downgrades
A number of equities analysts have weighed in on the stock. Wedbush restated an "outperform" rating and set a $35.00 price objective on shares of Zenas BioPharma in a research report on Thursday, May 15th. HC Wainwright reaffirmed a "buy" rating and set a $30.00 target price on shares of Zenas BioPharma in a report on Friday, May 16th.
Check Out Our Latest Stock Analysis on ZBIO
Zenas BioPharma Stock Down 4.3%
The firm has a 50-day moving average of $11.68. The firm has a market cap of $673.04 million and a price-to-earnings ratio of -4.53.
Zenas BioPharma (NASDAQ:ZBIO - Get Free Report) last posted its quarterly earnings data on Thursday, May 15th. The company reported ($0.80) earnings per share for the quarter, beating analysts' consensus estimates of ($1.15) by $0.35. The firm had revenue of $10.00 million during the quarter, compared to analysts' expectations of $5.00 million.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently made changes to their positions in the company. New York State Common Retirement Fund purchased a new stake in shares of Zenas BioPharma during the 1st quarter worth about $49,000. Nuveen LLC purchased a new position in shares of Zenas BioPharma during the 1st quarter valued at approximately $250,000. Finally, Jefferies Financial Group Inc. purchased a new position in shares of Zenas BioPharma during the 1st quarter valued at approximately $348,000.
About Zenas BioPharma
(
Get Free Report)
Zenas BioPharma, Inc is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Zenas BioPharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zenas BioPharma wasn't on the list.
While Zenas BioPharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
